Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026
Aligos Therapeutics announced that five abstracts were accepted for presentation at AASLD's The Liver Meeting 2026, held November 5-9, 2026 in Denver. Three abstracts cover pevifoscorvir sodium, a potential first-/best-in-class CAM-E for chronic hepatitis B, including data on HBsAg reduction below 3000 IU/mL in long-term treated HBeAg-positive subjects and a Poster of Distinction.
Key figures
- Drug Name
- pevifoscorvir sodium
- Abstracts accepted
- 5
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.